InspireMD, Inc.

NasdaqCM NSPR

InspireMD, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -50.80%

InspireMD, Inc. Return on Capital Employed (ROCE) is -50.80% for the year ending December 31, 2023, a 46.84% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

InspireMD, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -95.56%, a -129.64% change year over year.
InspireMD, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -41.61%.
InspireMD, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -148.06%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: NSPR

InspireMD, Inc.

CEO	Mr. Marvin L. Slosman
IPO Date	April 12, 2011
Location	Israel
Headquarters	4 Menorat Hamaor Street
Employees	65
Sector	Technology
Industries 3D Printing Biotechnology Composite Materials Defense & Military Eyewear Fintech Medical Instruments Robotics

Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Key trends

Past 5 years